Volume 66, Issue 2, Pages (August 2014)

Slides:

Advertisements

Similar presentations

Volume 68, Issue 6, Pages (December 2015)

Advertisements

Volume 59, Issue 2, Pages (February 2011)

The PSA Era is not Over for Prostate Cancer

Volume 50, Issue 1, Pages (July 2006)

Volume 60, Issue 2, Pages (August 2011)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Maurizio Brausi, Federica Rizzi, Saverio Bettuzzi European Urology

Testosterone Therapy in Men With Prostate Cancer

Volume 69, Issue 5, Pages (May 2016)

Volume 56, Issue 6, Pages (December 2009)

Volume 68, Issue 6, Pages e129-e131 (December 2015)

Volume 70, Issue 6, Pages (December 2016)

Volume 68, Issue 4, Pages (October 2015)

Control of Prostate Cancer by Transrectal HIFU in 227 Patients

Volume 69, Issue 5, Pages (May 2016)

Volume 70, Issue 2, Pages (August 2016)

Prostate Cancer Epidemic in Sight?

Volume 52, Issue 4, Pages (October 2007)

Volume 70, Issue 5, Pages (November 2016)

Volume 72, Issue 5, Pages (November 2017)

Volume 68, Issue 4, Pages (October 2015)

Volume 59, Issue 2, Pages (February 2011)

Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer Sam Ladjevardi, Gabriel Sandblom,

Volume 74, Issue 1, Pages (July 2018)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 67, Issue 2, Pages (February 2015)

Volume 54, Issue 4, Pages (October 2008)

Volume 63, Issue 6, Pages (June 2013)

Volume 53, Issue 4, Pages (April 2008)

Prostate Cancer Detection: A View of the Future

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 67, Issue 3, Pages (March 2015)

Volume 56, Issue 2, Pages (August 2009)

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 70, Issue 5, Pages (November 2016)

Volume 73, Issue 6, Pages (June 2018)

Volume 71, Issue 5, Pages (May 2017)

Volume 71, Issue 6, Pages (June 2017)

Volume 54, Issue 2, Pages (August 2008)

Volume 66, Issue 6, Pages (December 2014)

Luis Martínez-Piñeiro European Urology Supplements

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

Volume 53, Issue 2, Pages (February 2008)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 53, Issue 6, Pages (June 2008)

Volume 62, Issue 4, Pages (October 2012)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 74, Issue 2, Pages (August 2018)

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 71, Issue 2, Pages (February 2017)

Volume 70, Issue 2, Pages (August 2016)

Volume 50, Issue 5, Pages (November 2006)

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

Anna Grenabo Bergdahl, Erik Holmberg, Sue Moss, Jonas Hugosson

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 52, Issue 6, Pages (December 2007)

Volume 71, Issue 5, Pages (May 2017)

Volume 67, Issue 6, Pages (June 2015)

Volume 49, Issue 4, Pages (April 2006)

Maurizio Brausi, Federica Rizzi, Saverio Bettuzzi European Urology

Volume 70, Issue 1, Pages (July 2016)

European Urology is “Your” Journal

Volume 74, Issue 6, Pages (December 2018)

European Urology Oncology

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Volume 54, Issue 3, Pages (September 2008)

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Volume 54, Issue 1, Pages (July 2008)

Presentation transcript:

Volume 66, Issue 2, Pages 330-336 (August 2014) Initial Biopsy Gleason Score as a Predictive Marker for Survival Benefit in Patients with Castration-resistant Prostate Cancer Treated with Docetaxel: Data from the TAX327 Study Robert J. van Soest, Ellen S. de Morrée, Liji Shen, Ian F. Tannock, Mario A. Eisenberger, Ronald de Wit European Urology Volume 66, Issue 2, Pages 330-336 (August 2014) DOI: 10.1016/j.eururo.2013.08.007 Copyright © 2013 European Association of Urology Terms and Conditions

Fig. 1 Kaplan-Meier estimates of overall survival for the docetaxel (75mg/m2 every 3 wk) arm and the mitoxantrone (every 3 wk) arm in (A) the Gleason score 7–10 subgroup and (B) the Gleason score 2–6 subgroup. European Urology 2014 66, 330-336DOI: (10.1016/j.eururo.2013.08.007) Copyright © 2013 European Association of Urology Terms and Conditions